Oculis Holding Dirección

Dirección controles de criterios 0/4

El CEO de Oculis Holding's es Riad Sherif, nombrado en Dec 2017, tiene una permanencia de 6.33 años. posee directamente un 2.11% de las acciones de la empresa, con un valor de €9.72M. La antigüedad media del equipo directivo y de la junta directiva es de 2.2 años y 1.4 años, respectivamente.

Información clave

Riad Sherif

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	6.4yrs
Participación del CEO	2.1%
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	1.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Riad Sherif (55 yo)

6.4yrs

Permanencia

Dr. Riad Sherif, MD, MBA, has been the Chief Executive Officer and Director of Oculis Holding AG (formerly known as Oculis SA) since December 2017. He is Chief Executive Officer and Director of Oculis ehf....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Riad Sherif	CEO & Director	6.4yrs	sin datos	2.11% CHF 9.8m
Sylvia Cheung	Chief Financial Officer	3.7yrs	sin datos	0.16% CHF 747.5k
Ramin Tadayoni	Chief Scientific Officer	less than a year	sin datos	sin datos
Virginia Dean	Chief Human Resources Officer	less than a year	sin datos	sin datos
Bastian Dehmel	Chief Development Officer	2.3yrs	sin datos	sin datos
Páll Jóhannesson	Chief Business Officer	3.7yrs	sin datos	0.60% CHF 2.8m
Rebecca Weil	Chief Commercial Officer	less than a year	sin datos	sin datos
Snehal Shah	President of Research & Development	less than a year	sin datos	sin datos

1.5yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CR5 no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Riad Sherif	CEO & Director	6.4yrs	sin datos	2.11% CHF 9.8m
Eric Donnenfeld	Chair of Cornea Scientific Advisory Board	no data	sin datos	sin datos
Anthony Rosenberg	Independent Chairman	6.1yrs	sin datos	0.23% CHF 1.1m
Christophe Baudouin	Member of Scientific Advisory Board	1.5yrs	sin datos	sin datos
Peter Kaiser	Member of Scientific Advisory Board	1.5yrs	sin datos	sin datos
Lionel Carnot	Independent Director	6.4yrs	sin datos	sin datos
Pravin Dugel	Independent Director	1.2yrs	sin datos	0% CHF 0
Christina Ackermann	Independent Director	1.2yrs	sin datos	0.028% CHF 131.1k
Quan Dong Nguyen	Member of Scientific Advisory Board	1.5yrs	sin datos	sin datos
Arshad Khanani	Chair of Retina Scientific Advisory Board	1.5yrs	sin datos	sin datos
Anat Loewenstein	Member of Scientific Advisory Board	1.5yrs	sin datos	sin datos
Pablo Villoslada	Member of Scientific Advisory Board	1.5yrs	sin datos	sin datos

1.5yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de CR5 no se considera experimentada (1.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Oculis Holding Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

High number of new directors

High number of new directors

Recent updates

First quarter 2024 earnings released: CHF0.44 loss per share (vs CHF1.27 loss in 1Q 2023)

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million.

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG has completed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Full year 2023 earnings released: CHF2.97 loss per share (vs CHF12.95 loss in FY 2022)

New major risk - Revenue and earnings growth

Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease

Third quarter 2023 earnings released: CHF0.48 loss per share (vs CHF3.29 loss in 3Q 2022)

Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors

Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema

New major risk - Revenue and earnings growth

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

Second quarter 2023 earnings released: CHF0.38 loss per share (vs CHF3.29 loss in 2Q 2022)

Oculis Holding Ag Announces Positive Top Line Results from Its Phase 3 Optimize Trial with Ocs-01 Eye Drops

High number of new directors

Oculis Holding AG to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases

High number of new directors

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad